August 18, 2016
2 min read

Duodenal mucosal resurfacing confers short-term benefits in type 2 diabetes

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Adults with type 2 diabetes have significantly improved hyperglycemia in the short term after single-procedure duodenal mucosal resurfacing, published data show.

Harith Rajagopalan, MD, PhD, co-founder, CEO and director of Fractyl Laboratories Inc., and colleagues evaluated 39 adults with type 2 diabetes who underwent duodenal mucosal resurfacing using novel balloon catheters on varying lengths of duodenum to determine the procedural safety and glycemic indices at 6 months.

Ablation of a long segment of duodenal mucosal was performed in 28 participants and 11 had a short segment ablated.

Immediately after the procedure and at later follow-up visits, there was no gastrointestinal bleeding, perforation, pancreatitis, severe hypoglycemia or evidence of malabsorption. Transient postprocedural abdominal pain due to air insufflation and/or endotracheal intubation was the most common study-related adverse event. Discomfort was not reported by any participants by 48 hours after the procedure.

At 6 months, HbA1c was reduced by 1.2% in all participants (P < .001). At 3 months, the long segment of duodenal mucosal resurfacing group had a 2.5% reduction in mean HbA1c compared with a mean reduction of 1.2% in the short segment duodenal mucosal resurfacing group (P < .05 between groups). At 6 months, the trend continued in both groups (long segment, 1.4%; short segment, 0.7%; P = .3 between groups).

“Our findings suggest that minimally invasive upper gastrointestinal intervention through [duodenal mucosal resurfacing] can improve glycemia in type 2 diabetes and represents an interesting potential adjuvant or alternative to pharmacological treatment,” the researchers wrote. “The [duodenal mucosal resurfacing] approach may overcome treatment adherence and compliance issues, a major shortcoming of all pharmacological approaches. [Duodenal mucosal resurfacing] also provides a window into the intriguing and specific role of the duodenum in regulating downstream metabolism. Further work is necessary to better understand the clinical utility of this procedure-based intervention in controlled trial conditions in larger numbers of patients.” – by Amber Cox

Disclosure: Rajagopalan reports being an employee and owning shares in Fractyl Laboratories Inc.